Learn about the value of CRP Point-of-care testing for COPD and Antimicrobial in the context of Covid-19
Check out the on-demand symposium recording from the European Respiratory Society congress 2020 by clicking here. Learn how C-reactive protein (CRP) point-of-care testing can be a valuable diagnostic and clinical decision-making tool in relation to COVID-19, and how it may also inform antibiotic prescribing for acutely exacerbated chronic obstructive pulmonary disease (COPD) patients.
The European Respiratory Society congress (ERS) was held on 7–9 September 2020 and delivered the latest innovations in respiratory medicine to over 33,000 delegates.
myPOCacademy hosted a virtual symposium covering CRP point-of-care testing in the time of COVID-19 and for the reduction of antibiotic prescribing in acutely exacerbated COPD patients, watched live by nearly 500 healthcare professionals.
Hear expert perspectives on the value of C-reactive protein (CRP) point-of-care testing (POCT) in the context of COVID-19 by watching the on-demand symposium recording which is now available exclusively on myPOCacademy.
Featuring expert opinion from front-line healthcare staff from around the world, discussions centered around the following topics:
- CRP level as an inflammatory marker for severity and risk assessment in COVID-19
- CRP POCT for identification of patients at high risk of severe outcomes in COVID-19
- CRP POCT for optimal allocation of hospital and intensive care unit resources
- CRP POCT to aid clinical decision-making and guide antibiotic prescribing in patients presenting with symptoms of respiratory tract infections
- The role of CRP POCT in the fight against anti-microbial resistance
- CRP POCT as a diagnostic strategy in patients presenting with acute exacerbation of chronic obstructive pulmonary disease (COPD) in primary care (the PACE study)
Click here to watch the ERS symposium recording in full.